Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial

Gelderblom, Harald; Wüstenberg, Torsten; McLean, Tim; Mütze, Lisanne; Fischer, Wilhelm; Saft, Carsten; Hoffmann, Rainer; D. Süßmuth, Sigurd; Schlattmann, Peter; van Duijn, Erik; Bernhard Landwehrmeyer, G.; Priller, Josef

doi:10.1371/journal.pone.0173872

Public

Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial

Published in PLoS ONE • Mar 21, 2017

Authors:

Harald Gelderblom

Torsten Wüstenberg

Tim McLean

Abstract

OBJECTIVE: To evaluate the efficacy and safety of bupropion in the treatment of apathy in Huntington's disease (HD). METHODS: In this phase 2b multicentre, double-blind, placebo-controlled crossover trial, individuals with HD and clinical signs of apathy according to the Structured Clinical Intervie...

Subject

Apathy

Bupropion

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!